Area of research
Oncology · Genetics
Research interest
Research interests include PARP inhibition in cancer therapy, BRCA gene mutations in cancer, DNA Repair Mechanisms, and Ovarian cancer diagnosis and treatment.
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.
Homologous Recombination Deficiency: Concepts, Definitions, and Assays
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes
Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer
<i>BRCA1</i>Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis
Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and <i>BRCA1/2</i> Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors
Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or <i>BRCA1/2</i> breast cancer (CRUK/07/012)
Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)
Frequency of mutations in individuals with breast cancer referred for <scp><i>BRCA</i></scp><i>1</i> and <scp><i>BRCA</i></scp><i>2</i> testing using next‐generation sequencing with a 25‐gene panel
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer